Announces private investment
Eyen will become the first public listed company based in the United States to hold media threw in its treasure
Hyunsu Jung appointed the investment director and member of the board of directors
Laguna Hills, California, June 17, 2025 (Globe Newswire) – Eyenovia, Inc. (Nasdaq: Eyen) (“Eyenovia” or “Company”) announced today that it had concluded a value purchase agreement
In accordance with the terms and conditions of the SPA, the company will issue the convertible convertible action not voting in approximately 15.4 million ordinary shares of the company at a conversion price
“We are pleased to join the growing number of companies that have adopted similar strategies for diversification, liquidity and the long-term capital assessment potential represented by cryptocurrency,” said Michael Rowe, CEO of Eyenovia. “Following an in -depth examination of all the alternatives available, the board of directors and I concluded that this transaction is in the best interests of our shareholders.”
Mr. Jung added: “I am honored and delighted to join the Eyenovia team to help direct this pioneering cryptocurrency treasury strategy built around what we believe is the most robust digital asset, media threw. We consider hyperliquid as one of the fastest and highest highest blockchains generating the highest in the world. ”
The funding of pipes allows the company to acquire more than 1,000,000 media threshing, enough to become one of the best active validators for hyperliquidal – and the first to be listed on the NASDAQ. As part of the strategy, the company also intends to implement a media threshing implementation program while securing assets thanks to a partnership with Digital Anchorage. This transaction aligns the business vision of creating long -term value for shareholders by capitalizing on the global adoption of blockchain and digital innovation.
In addition to its new cryptocurrency treasury strategy, the company will continue to focus on its existing activities, including the development of the apparatus filled with Optejet (UFD), which the company plans to register with the FDA by September 2025.
The fence of the offer should occur on June 20, 2025, subject to the satisfaction of customary closing conditions, the company should also change its name and its “Hyperion Defi” and “Hyperion”.
Chardan acts as a unique placement agent in relation to the transaction.
The offer and sale of the above securities are made in a transaction not involving a public offer, and the titles have not been recorded under the ACT Securities of 1933, as modified, and cannot be reorganized or submitted to the United States, except under an effective recording declaration or an applicable exemption from the recording requirements. In addition to the execution of the SPA, the company and the investors concluded a registration rights agreement, under which the company agreed to file a registration declaration with the Securities and Exchange Commission (the “dry”) recorded the resale of the ordinary shares underlying the privileged shares and the mandates.
This press release will not constitute an offer of sale or a request for an offer to purchase these titles, and there will be no sale of these titles in a state or other jurisdiction in which such an offer, solicitation or sale would be illegal before registration or qualification under the laws in matters of any state or other jurisdiction.
Nasdaq 5635 rule (c) (4) Notice
As part of the start of his job at the company, Mr. Jung obtained an incentive subsidy of 500,000 ordinary shares. The Committee for the Compensation of the Board of Directors of the Company approved the sentence as an incentive equipment for the employment of Mr. Jung in accordance with rule 5635 (c) (4) of the registration of the NASDAQ.
About the braking token
The media threshing is the native token of the hyperliquid layer of a blockchain (L1). Media threshing is marked out or delegated to validators participating in the personalized consensus algorithm of the network, Hyperbft, which is optimized for the logic of the order book and allows users to negotiate spactive and ultimately non -guardian and head markets. The marked media threshing more unlocks the utility in the form of discounts on negotiation costs, with reference bonuses and markets deployed by the manufacturer (HIP-3) to be introduced in the future. The media in circulation in circulation is bought independently and kidnapped with negotiation costs accumulated on the registered markets of the network. In June 2025, media threw became the 12th largest cryptocurrency by market capitalization.
About Eyenovia, Inc.
Eyenovia, Inc. is a pioneering company of digital technology in ophthalmia and the first company listed on the public stock market to build a long -term strategic treasure of the native token of hyperliquid, the beateering. With this double home, Eyenovia continues to revolutionize a topical eye treatment while providing its shareholders with simplified access to the hyperliquid ecosystem, one of the fastest and highest income -generating block chains in the world. Shareholders should benefit from a gradually aggravating exposure to the media threshing, both from its native return and additional income generated by ONCHAIN in a unique way of opportunities.
Eyenovia is also developing its Optejet Propietary Optejet (UFD) opte project which is designed to operate with a variety of topical ophthalmic liquids, including artificial tears and objective RECWET products, covering several billion dollars. The project is particularly useful in chronic diseases on the front of the eye due to its improved ease of use, safety and tolerability and higher compliance potential compared to standard eye drops. Together, these advantages can cause compliance with higher treatment and better results for patients and providers.
For more information, please visit Eyenovia.com.
Front instructions
With the exception of historical information, all the declarations, expectations and hypotheses contained in this press release are prospective declarations. Prospective declarations include, without limiting themselves, the declarations that express our intentions, our beliefs, our expectations, our strategies, our forecasts or any other declaration, our future activities or other future events or conditions, including the planned use of the net product financing product, the expected moment of the financing of pipes The advantages of management change, the market opportunities estimated for our platform technology, Risks associated with our new cryptocurrency treasury strategy, clinical trials that may be necessary in relation to the authorization of the UFD opte project and the time of sales growth of our approved products. These declarations are based on current expectations, estimates and projections concerning our company, in part, on the hypotheses made by management. These declarations are not guarantees of future performance and imply risks, uncertainties and hypotheses that are difficult to predict. Consequently, the real results and the results can, and in some cases, are likely to differ materially from what is expressed or provided in prospective declarations due to many factors discussed from time to time in documents that we deposit with the dry.
In addition, such declarations could be affected by the risks and uncertainties linked, among other things: the risks of our clinical trials, including, but without limiting ourselves, market conditions and satisfaction of closing conditions; The potential advantages of our products and platform technology; the rate and degree of acceptance of the market and the clinical utility of our products; Our estimates concerning the potential market opportunity of our products; depended on third parties to develop and market our products; the ability of us and our partners to develop, implement and maintain manufacturing, marketing and marketing and strategies for our products; risks of intellectual property; Changes in legal, regulatory, legislative and geopolitical environments on the markets in which we operate and the impact of these changes on our ability to obtain the regulatory approval of our products and candidate products; our competitive position; And our ability to collect additional funds to maintain our commercial operations and make payments on our debt obligations as necessary.
All prospective declarations only speak on the date on which they are made, and unless it may be required under the laws applicable on securities, Eyenovia does not commit any obligation to update prospective declarations.
Eyenovia Investor Contact:
Eric Ribner
Lifesci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
